Circulating Tumor DNA in Soft Tissue Sarcoma

Sponsor
University Health Network, Toronto
Study ID
NCT03818412
Status
Recruiting
Apply to this trial

Conditions

  • Soft Tissue Sarcoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Archival tumor tissue collection and blood draws — PROCEDURE
    Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.

Study Details

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.

Key Dates

First listed
Jan 28, 2019
Start date
Jan 17, 2019
Status verified
Jun 2026
Primary completion
Dec 17, 2026
Completion
Dec 17, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Soft Tissue Sarcoma
    A sample of archival tumor tissue will be collected. Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken: * Prior to planned radiation treatment * 2-4 weeks after cancer surgery * Every 12 weeks after surgery for up to 2 years

Primary Outcome Measure

Number of patients with demonstrable circulating tumor DNA (ctDNA) quantification [ Time Frame: 5 years ]

Central Contacts

Related Studies